Skip to content
AnalystLens

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Feb 5, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 5, 2024
Period End
February 5, 2024
Security
VRTX
In the record · 2016–202610-K1110-Q328-K100

VRTX filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 100 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Oct ’17Oct ’17
  2. Leadership change8-K · Apr ’20Apr ’20
  3. Material agreement8-K · Jul ’22Jul ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed February 5, 2024. Cited figures are marked; the original filing is the authoritative source.

Vertex Pharmaceuticals (VRTX) reported fourth quarter and full-year 2023 results on February 5, 2024, filed under Item 2.02 with the press release attached as Exhibit 99.1.

Full-year 2023 product revenue rose 11% to $9.87 billiona, driven by TRIKAFTA/KAFTRIO in ex-U.S. markets and continued TRIKAFTA growth in the U.S., including the launch in children aged 2 to 5. U.S. product revenue grew 6% to $6.04 billion, while ex-U.S. revenue grew 18% to $3.83 billion. Full-year GAAP net income rose 9% to $3.62 billion, and non-GAAP net income rose 3% to $3.97 billion.

Cash and marketable securities ended the year at $13.7 billionb, up from $10.9 billion. Note that the balance sheet in the filing shows $11.2 billion of cash and marketable securities plus $2.5 billion of long-term marketable securities, which together account for the $13.7 billion figure. Management guided to 2024 product revenue of $10.55 to $10.75 billion, with non-GAAP R&D, acquired IPR&D and SG&A expenses of $4.3 to $4.4 billion and a non-GAAP effective tax rate of 20% to 21%.

Combined GAAP expenses are guided to $4.9 to $5.1 billionc, and the gap is mainly stock-based compensation. Combined expense growth in 2023 was elevated by acquired IPR&D, which rose to $527 million from $116 million. Fourth-quarter product revenue grew 9% to $2.52 billion, but GAAP operating income fell about 4% year over year to $988.5 million as R&D and SG&A costs rose.

The main investor catalysts are regulatory and commercial. Vertex plans to file NDAs and related applications by mid-2024 for vanzacaftor/tezacaftor/deutivacaftor in CF and for VX-548 in acute pain.

CASGEVY has been approved in the U.S., Great Britain, Bahrain and Saudi Arabia for sickle cell disease and transfusion-dependent beta thalassemia, and the company is working to secure reimbursement and expand treatment centers. Pipeline milestones include the inaxaplin Phase 3 start in APOL1-mediated kidney disease in Q1 2024, and VX-880 remains on a protocol-specified pause.

02—Key points

Key Highlights

  1. FY2023 product revenue rose 11% to $9.87 billion, with ex-U.S. revenue up 18% to $3.83 billion and U.S. revenue up 6% to $6.04 billion.
  2. Q4 2023 product revenue grew 9% to $2.52 billion, led by TRIKAFTA/KAFTRIO sales of $2.33 billion.
  3. FY2024 product revenue guidance is $10.55 to $10.75 billion, with non-GAAP combined R&D, acquired IPR&D and SG&A expenses of $4.3 to $4.4 billion.
  4. GAAP net income rose 9% to $3.62 billion for FY2023, and non-GAAP net income rose 3% to $3.97 billion, helped by higher interest income and lower taxes.
  5. Cash and marketable securities reached $13.7 billion at year-end 2023, up from $10.9 billion a year earlier.
  6. Vanzacaftor triple and VX-548 NDA submissions are targeted by mid-2024, with the vanzacaftor triple using a priority review voucher.
  7. CASGEVY has received approvals in the U.S., Great Britain, Saudi Arabia and Bahrain, and the company is activating authorized treatment centers and pursuing reimbursement.

03—Questions

Frequently Asked Questions

  1. How did Vertex perform financially in 2023?

    Vertex reported FY2023 product revenue of $9.87 billion, up 11% year over year. GAAP net income was $3.62 billion, up 9%, and non-GAAP net income was $3.97 billion, up 3%. Growth was driven mainly by TRIKAFTA/KAFTRIO, especially in ex-U.S. markets.

  2. What is Vertex's 2024 guidance?

    Vertex guided to 2024 product revenue of $10.55 to $10.75 billion. Non-GAAP combined R&D, acquired IPR&D and SG&A expenses are expected to be $4.3 to $4.4 billion, and the non-GAAP effective tax rate is expected to be 20% to 21%. GAAP combined expenses are guided higher, at $4.9 to $5.1 billion, mainly because of stock-based compensation.

  3. Why did U.S. revenue grow more slowly than ex-U.S. revenue?

    U.S. product revenue grew 6% in 2023 to $6.04 billion, while ex-U.S. revenue grew 18% to $3.83 billion. The filing attributes the ex-U.S. strength to continued uptake of TRIKAFTA/KAFTRIO and label extensions to younger age groups, while U.S. growth reflected continued TRIKAFTA performance, including the launch in children aged 2 to 5.

  4. What are the key near-term catalysts for investors?

    The main catalysts are the planned mid-2024 regulatory submissions for vanzacaftor triple in CF and VX-548 in acute pain, the start of the inaxaplin Phase 3 portion in APOL1-mediated kidney disease in Q1 2024, and the commercial rollout of CASGEVY. Investors should also watch the status of the VX-880 type 1 diabetes study, which is on a protocol-specified pause.

  5. How is the CASGEVY launch progressing?

    CASGEVY is approved in the U.S., Great Britain, Saudi Arabia and Bahrain for sickle cell disease and transfusion-dependent beta thalassemia. Vertex has activated 12 authorized treatment centers in the U.S. and three in the EU, with a goal of about 50 in the U.S. and 25 in Europe. Reimbursement remains a key factor, and the filing notes that the CMS Cell and Gene Therapy Access Model begins in January 2025.

04—Continue

← View all 8-K filings